Have you been diagnosed with relapsed or refractory multiple myeloma? If so, you may be able to take part in a research study looking at the safety and tolerability of giving a new drug called ABBV-453 alone and in combination with other antimyeloma drugs to patients with relapsed or refractory multiple myeloma.

Do you have asthma? Would you like to learn about a new medicine that might help? We are looking for people aged 18-65 with asthma to join our study. You will be paid for your time. Compensation is provided.

The purpose of this study is to gather insight directly from people with eating disorders or who have cared for someone with an eating disorder about the ways the eating disorder has impacted areas of their life including education, work, social relationships, and participation in recreational or community activities.

We're inviting people receiving lumpectomies for breast cancer to take part in a study looking at skin discoloration after the use of Magtrace®, a tracer already used to map sentinel lymph nodes during breast surgery. This research aims to understand how often skin discoloration occurs and how it affects patients over time. Participation involves questionnaires and skin imaging.

The researchers at the UNC Food Allergy Initiative are looking for children with cashew allergies to participate in a research study in Chapel Hill. Specifically, this study will see if an experimental treatment using cashew drops placed under the tongue (sublingual immunotherapy, SLIT) for approximately 18 months can increase the amount of cashew that can be eaten safely without symptoms. This is called desensitization.

Do you have protein in your urine and have had a kidney biopsy? You may be able to participate in a research study to test to see if a study drug can reduce the amount of protein in your urine.

The purpose of this study is to learn how microbes in the uterus and gut (bacteria, viruses, fungi) and your own innate immune system (the first line of defense of the body) impacts how well certain treatments work for endometrial cancer. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.

Were you diagnosed with type 1 diabetes in the last few weeks? We are looking for people who are able to come in for a single visit within 2 months of their diagnosis of type 1 diabetes to collect demographic data and a blood sample. We will be collecting blood for the analysis of a specific genotype to see its distribution among people who are diagnosed with T1D.

Do you speak Spanish or identify as Hispanic or Latino and have cancer? You can help improve cancer care by sharing your experience. We need patients to complete a one-time survey about your health, background, and cancer treatment. Your input is important and can help others receive better care. Participation involves only a one-time survey, with no required medical tests. ¿Es usted un adulto hispano, latino o de habla hispana con cáncer? Puede ayudar a mejorar la atención del cáncer al compartir su experiencia. Le pedimos a los pacientes que completen una encuesta una sola vez sobre su salud, antecedentes y atención médica durante o después del tratamiento. Su voz es importante y puede ayudar a que otros reciban mejor atención. La participación consiste únicamente en una encuesta, sin pruebas médicas obligatorias.

This research study aims to investigate the use of circulating tumor DNA (ctDNA) monitoring to detect early signs of cancer recurrence in patients with triple-negative breast cancer (TNBC) after standard treatment. TNBC is aggressive and has a higher risk of recurrence, often detected only after symptoms appear. This study will monitor ctDNA levels through blood samples collected during and after adjuvant therapy. If ctDNA is not detected, participants will continue monitoring. If ctDNA is detected, the study offers an investigational treatment, datopotamab deruxtecan (Dato-DXd), to address this potential recurrence risk. Participation in this study will help determine if ctDNA monitoring can improve the early detection of recurrence and potentially lead to better treatment strategies and outcomes for patients with TNBC in the future.